University of Washington

Health Systems and Population Health

SCHOOL OF PUBLIC HEALTH

Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.


  1. Home


  2. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.


  3. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.

rakerr2

Ackerman SJ, Sullivan EM, Beusterien KM, Natter HM, Gelinas DF, Patrick DL. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS. Pharmacoeconomics. 1999 Feb;15(2):179-95.

Upcoming Events

Full Calendar

News Categories